FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average I	burden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*				2. Is	2. Issuer Name and Ticker or Trading Symbol											5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Krogulski Kenneth						CUMBERLAND PHARMACEUTICALS INC [ CPIX ]										X	Director  Officer (give title		10% C		(specify	
(Last) (First) (Middle) 2525 WEST END AVENUE SUITE 950						3. Date of Earliest Transaction (Month/Day/Year) 11/20/2017											belov	w)		below)		
(Street)  NASHVILLE TN 37203					_ 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person						
(City)	(:	State)	(Zip)														Form Pers	n filed by Mo on	re than (	One Rep	orting	
		Ta	ole I - No	n-Deriv	/ative	Se	curit	ies Ac	quire	ed, Di	spos	ed o	f, oı	r Ben	efici	ally	Owne	ed				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution			Co	Transaction Dispos			rities Acquired (A) ed Of (D) (Instr. 3,				5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Co	ode V	Am	Amount		(A) or (D) Price		Tran		action(s) 3 and 4)			(111511.4)	
Common Stock 11/20/					0/2017	7				P		3,300		0 A S		.55	55 154,300		I	)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year	3A. Deem Executior if any (Month/Da	n Date,		ransaction Code (Instr.		of		ate Exerc ration Da nth/Day/\	ate			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			ivative urity	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	m: ect (D) ndirect	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	cisable	Expir Date	ation	Title	or Nui of	Number							

**Explanation of Responses:** 

Remarks:

Kenneth J. Krogulski by /s/

Michael Bonner as attorney-in- 11/24/2017

fact

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.